Ert Pompe denied as not FDA-approved for this use by AmeriHealth Caritas?

Confirmed enzyme assay + genetic testing. Specialist Rx (geneticist or metabolic).

EPSDT for under-21 overrides state PDL limits. Orphan Drug Act + FDA approval rebut 'experimental' label. Site-of-care: home infusion appropriate for stable patients per manufacturer REMS.

## Why AmeriHealth Caritas May Deny ERT for Pompe Disease as "Not FDA-Approved"

Enzyme replacement therapy (ERT) for Pompe disease has received FDA approval, which means a denial coded as "not FDA-approved" is typically the result of a coding mismatch, an outdated formulary system entry, or a misclassification of the specific ERT product or indication in your claim. These administrative errors are among the most correctable denial types on appeal.

## Why This Denial Is Appealable

If your prescriber has ordered an ERT product that holds FDA approval for Pompe disease, the insurer's own coverage standards almost certainly require them to consider it. A factual correction — supported by documentation — can overturn this type of denial at the first internal-appeal level without requiring external review.

## Federal Appeal Framework

You have layered protections: - Internal appeal: Submit within the timeframe on your Explanation of Benefits (EOB), typically 180 days. AmeriHealth Caritas must respond within 30 days for non-urgent requests (72 hours for expedited). - External review (ACA §2719): If the internal appeal is denied, you may request an independent external review. Pompe disease is a serious, progressive condition, so expedited external review is often appropriate — insurers must respond to expedited requests within 72 hours. - ERISA §503 (if employer-sponsored): You have the right to a full-and-fair review of all claim-related documents. Request the complete claims file, including the clinical criteria the plan used.

The external-review window is generally four months from the date of final internal denial.

## Documentation to Gather

• FDA approval confirmation: The prescribing label for the specific ERT product, confirming its FDA-approved indication for Pompe disease.
• Diagnosis documentation: Genetic testing results (GAA gene mutation), enzyme activity assay results, and the formal Pompe disease diagnosis from a qualified specialist (typically a metabolic disease or neuromuscular specialist).
• Prior treatment history: Any prior ERT exposure, treatment dates, and clinical response or tolerability notes.
• Medical necessity letter: A detailed letter from the treating physician explaining why this specific ERT product is indicated, referencing the FDA label and applicable specialist-society guidelines.
• Claim coding review: Ask your specialty pharmacy or prescriber's billing team to verify the NDC code and diagnosis code submitted match the FDA-approved indication exactly.

## Criteria-Mapping Structure

Copy each coverage requirement from the AmeriHealth Caritas published medical policy for ERT in Pompe disease. Then, for each requirement, provide the specific chart fact that satisfies it:

| Policy Requirement | Supporting Documentation | |---|---| | FDA-approved product for stated indication | [Prescribing label + specific NDC] | | Confirmed Pompe disease diagnosis | [Genetic/enzyme test report + specialist note] | | Prescriber specialty requirement (if any) | [Treating physician credentials] |

A cover letter clearly noting "This denial appears to be based on a factual error — the requested product holds FDA approval for this indication" frames the appeal effectively from the outset.